Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;32(4):989-1003.
doi: 10.1007/s11136-022-03327-4. Epub 2023 Jan 11.

Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after

Carme Miret  1   2   3 , Miren Orive  4   5   6   7 , Maria Sala  2   6 , Susana García-Gutiérrez  8   5   6   7 , Cristina Sarasqueta  6   7   9 , Maria Jose Legarreta  8   5   6   7 , Maximino Redondo  6   7   10 , Amado Rivero  11 , Xavier Castells  2   6 , José M Quintana  8   5   6   7 , Olatz Garin  3   12 , Montse Ferrer  13   14   15 ; REDISSEC-CaMISS Group
Collaborators, Affiliations

Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after

Carme Miret et al. Qual Life Res. 2023 Apr.

Erratum in

Abstract

Purpose: To obtain reference norms of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L, based on a population of Spanish non-metastatic breast cancer patients at diagnosis and 2 years after, according to relevant demographic and clinical characteristics.

Methods: Multicentric prospective cohort study including consecutive women aged ≥ 18 years with a diagnosis of incident non-metastatic breast cancer from April 2013 to May 2015. Health-related quality of life (HRQoL) questionnaires were administered between diagnosis and beginning the therapy, and 2 years after. HRQoL differences according to age, comorbidity and stage were tested with ANOVA or Chi Square test and multivariate linear regression models.

Results: 1276 patients were included, with a mean age of 58 years. Multivariate models of EORTC QLQ-C30 summary score and EQ-5D-5L index at diagnosis and at 2-year follow-up show the independent association of comorbidity and tumor stage with HRQoL. The standardized multivariate regression coefficient of EORTC QLQ-C30 summary score was lower (poorer HRQoL) for women with stage II and III than for those with stage 0 at diagnosis (- 0.11 and - 0.07, p < 0.05) and follow-up (- 0.15 and - 0.10, p < 0.01). The EQ-5D-5L index indicated poorer HRQoL for women with Charlson comorbidity index ≥ 2 than comorbidity 0 both at diagnosis (- 0.13, p < 0.001) and follow-up (- 0.18, p < 0.001). Therefore, we provided the reference norms at diagnosis and at the 2-year follow-up, stratified by age, comorbidity index, and tumor stage.

Conclusion: These HRQoL reference norms can be useful to interpret the scores of women with non-metastatic breast cancer, comparing them with country-specific reference values for this population.

Keywords: Breast cancer; EORTC; EQ-5D-5L; Health-related quality of life; Reference values.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
EQ-5D-5L Index according to age, tumor stage and Charlson Comorbidity Index: bars represent means and their 95% confidence intervals at diagnosis and at 2-year follow-up. Discontinuous lines represent the EQ-5D-5L index means of reference norms based on general population [15] Spanish women. Y axis represents the EQ-5D-5L index values from 1 (perfect health) to 0 (death). *p value < 0.05 obtained using Tukey post hoc analysis for comparing each category with the reference: aged < 40 years old, tumor stage 0, or Charlson Comorbidity Index 0
Fig. 2
Fig. 2
EORTC QLQ-C30 summary score according to age, tumor stage and Charlson Comorbidity Index: bars represent means and their 95% confidence intervals at diagnosis and at 2-year follow-up. Discontinuous lines represent the EORTC QLQ-C30 reference norms based on patients with non-metastatic breast cancer at diagnosis [21]. Y axis represents the EORTC QLQ-C30 summary score from 0 (worst) to 100 (best results). *p value < 0.05 obtained using Tukey post hoc analysis for comparing each category with the reference: aged < 40 years old, tumor stage 0, or Charlson Comorbidity Index 0
See this image and copyright information in PMC

References

    1. Kohler B, Sherman R, Howlader N, Jemal A, Ryerson A, Henry K. Annual Report to the Nation on the Status of Cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. Journal of National Cancer Institute. 2015;107(6):djv048. doi: 10.1093/jnci/djv048. - DOI - PMC - PubMed
    1. Taira N, Shimozuma K, Shiroiwa T, Ohsumi S, Kuroi K, Saji S, et al. Associations among baseline variables, treatment-related factors and health-related quality of life 2 years after breast cancer surgery. Breast Cancer Research and Treatment. 2016;128(3):735–747. doi: 10.1007/s10549-011-1631-y. - DOI - PubMed
    1. Chu W, Dialla PO, Roignot P, Bone-Lepinoy MC, Poillot ML, Coutant C, et al. Determinants of quality of life among long-term breast cancer survivors. Quality of Life Research. 2016;25(8):1981–1990. doi: 10.1007/s11136-016-1248-z. - DOI - PubMed
    1. Smyth EN, Shen W, Bowman L, Peterson P, John W, Melemed A, et al. Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer. Health and Quality of Life Outcomes. 2016;14(52):1000. - PMC - PubMed
    1. Rautalin M, Färkkilä N, Sintonen H, Saarto T, Taari K, Jahkola T, et al. Health-related quality of life in different states of breast cancer—Comparing different instruments. Acta Oncologica. 2017;57(5):622–628. doi: 10.1080/0284186X.2017.1400683. - DOI - PubMed